See more : Sikri Group ASA (SIKRI.OL) Income Statement Analysis – Financial Results
Complete financial analysis of NEXGEL, Inc. (NXGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NEXGEL, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Modular Medical, Inc. (MODD) Income Statement Analysis – Financial Results
- Post Holdings Partnering Corporation (PSPC-UN) Income Statement Analysis – Financial Results
- Alla Public Company Limited (ALLA.BK) Income Statement Analysis – Financial Results
- Duke Royalty Limited (DUKE.L) Income Statement Analysis – Financial Results
- Fu Shou Yuan International Group Limited (1448.HK) Income Statement Analysis – Financial Results
NEXGEL, Inc. (NXGL)
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 4.09M | 2.05M | 1.55M | 674.00K | 717.00K | 2.21M | 1.99M | 2.15M |
Cost of Revenue | 3.47M | 1.79M | 1.54M | 965.00K | 854.00K | 1.70M | 1.85M | 2.27M |
Gross Profit | 619.00K | 256.00K | 9.00K | -291.00K | -137.00K | 514.00K | 147.00K | -114.00K |
Gross Profit Ratio | 15.14% | 12.50% | 0.58% | -43.18% | -19.11% | 23.23% | 7.38% | -5.30% |
Research & Development | 103.00K | 367.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 3.02M | 2.38M | 2.54M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 620.00K | 436.00K | 320.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.99M | 3.24M | 2.54M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
Other Expenses | 0.00 | 3.00K | 13.00K | 8.00K | 0.00 | 0.00 | 0.00 | 25.00K |
Operating Expenses | 4.10M | 3.60M | 2.58M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
Cost & Expenses | 7.57M | 5.40M | 4.12M | 2.93M | 2.64M | 4.10M | 2.96M | 4.02M |
Interest Income | 0.00 | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 15.00K | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 443.00K | 301.00K | 113.00K | 50.00K | 67.00K | 322.00K | 316.00K | 324.00K |
EBITDA | -2.73M | -3.11M | -2.20M | -2.20M | -1.86M | -1.57M | -653.00K | -1.54M |
EBITDA Ratio | -66.76% | -148.63% | -158.41% | -326.71% | -259.00% | -70.76% | -32.78% | -71.56% |
Operating Income | -3.48M | -3.35M | -2.57M | -2.26M | -1.92M | -1.89M | -969.00K | -1.86M |
Operating Income Ratio | -85.03% | -163.48% | -165.70% | -335.31% | -268.34% | -85.31% | -48.64% | -86.62% |
Total Other Income/Expenses | 289.00K | -1.40M | -1.74M | -4.00K | 1.00K | 0.00 | 0.00 | 25.00K |
Income Before Tax | -3.19M | -4.75M | -4.31M | -2.26M | -1.92M | -1.89M | -969.00K | -1.84M |
Income Before Tax Ratio | -77.97% | -231.74% | -277.89% | -335.91% | -268.20% | -85.31% | -48.64% | -85.46% |
Income Tax Expense | 0.00 | 1.40M | 2.00M | 18.00K | -104.86K | 160.86K | -16.00K | -63.00K |
Net Income | -3.16M | -6.14M | -6.31M | -2.28M | -1.92M | -1.89M | -953.00K | -1.78M |
Net Income Ratio | -77.21% | -300.00% | -406.71% | -338.58% | -268.20% | -85.31% | -47.84% | -82.53% |
EPS | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
EPS Diluted | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
Weighted Avg Shares Out | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
Weighted Avg Shares Out (Dil) | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
NEXGEL, Inc. (NXGL) Q3 2023 Earnings Call Transcript
3 Stocks You'll Regret Not Buying Soon: November 2023
NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
NEXGEL announces supply agreement with AbbVie
NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd
NEXGEL, Inc. (NXGL) Q2 2023 Earnings Call Transcript
Nexgel posts record 2Q revenue on contract manufacturing surge
NEXGEL to Report Second Quarter 2023 Financial Results on August 14th
NEXGEL announces retail distribution partnership with Enigma Health
NEXGEL Partners with Enigma Health to Distribute its Leading Products in Retail Stores throughout North America
Source: https://incomestatements.info
Category: Stock Reports